Side Effects of Cancer Treatments for CTEP Clinical Trials
The downloadable lists of side effects on this page describe possible side effects that may be experienced by patients taking commonly used commercially-available cancer therapy drugs or multiple-drug regimens. These documents are intended for use in the Informed Consent Documents or Patient Educational Materials developed for CTEP-supported clinical trials and reviewed by the NCI CIRB, but the documents on this page have not been approved by the NCI CIRB.
Side effect tables for CTEP IND agents will be provided directly to the lead organization during protocol development.
Resources for Developing Informed Consent Side Effect Tables
- To create tables for commercially-available drugs or regimens that are not available here, follow the instructions for Building Tables of Possible Side Effects for Commercial Agents (Word)
- To create tables for agents that are not commercially available, follow the instructions for Building Tables of Possible Side Effects for Investigational Agents (Word)
- Refer to the CTEP Informed Consent Risk Term Library and CTCAE IC Terms (Excel) to identify the appropriate terms
Comments and questions can be directed to NCICTEPComments@mail.nih.gov.
CTEP-Provided Tables of Side Effects
The downloadable lists of side effects on this page describe possible side effects that may be experienced by patients taking commonly used commercially-available cancer therapy drugs or multiple-drug regimens. These documents are intended for use in the Informed Consent Documents developed for CTEP-supported clinical trials and reviewed by the NCI CIRB.
The documents on these pages are provided as a resource for research staff and consent authors. These documents are not approved by the NCI CIRB as patient information sheets for use in conjunction with a clinical trial.
Before any materials can be used for patient education in conjunction with a clinical trial, they must be approved by the IRB of record. US sites participating in CTEP-supported clinical trial networks can find protocol-specific NCI CIRB-approved patient educational materials on the protocol page on the CTSU website.
Find and Download a List of Drug Side Effects
Browse drugs alphabetically below or type CTRL+F to search the page for a specific drug name. For a regimen or combination of multiple cancer-treatment drugs, find the entry that includes ALL the drugs in the regimen.
5
- 5-Fluorouracil (Jan 13, 2025)
- 5-Fluorouracil, Leucovorin (Jan 13, 2025)
- 5-Fluorouracil, Mitomycin (Jan 13, 2025)
- 5-Fluorouracil, Oxaliplatin, Docetaxel (FLOT) (Mar 31, 2025)
- 5-Fluorouracil, Oxaliplatin, Paclitaxel (2021)
A
- Abiraterone (2023)
- ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine) (2022)
- Anastrozole (2023)
- Arsenic Trioxide (2023)
- Asparaginase Erwinia chrysanthemi (2024)
- AVD (Doxorubicin, Vinblastine, Dacarbazine) (2022)
B
- BEACOPP (Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone) (2022)
- Bendamustine (2022)
- Bicalutamide (2023)
- Bleomycin (2024)
- Bleomycin, Etoposide, Cisplatin (2024)
- Busulfan (2023)
C
- Cabazitaxel (2022)
- Cabazitaxel, Prednisone (2022)
- Calaspargase (see Pegaspargase)
- Capecitabine (2023)
- Carboplatin (2024)
- Carboplatin, Cyclophosphamide, Vincristine (Apr 4, 2025)
- Carboplatin, Etoposide (Apr 2, 2025)
- Carboplatin, Etoposide, Ifosfamide (Apr 2, 2025)
- Carboplatin, Etoposide, Melphalan (Apr 2, 2025)
- Carboplatin, Etoposide, Vincristine (Apr 2, 2025)
- Carboplatin, Paclitaxel (2024)
- Carboplatin, Pemetrexed (Feb 13, 2025)
- Carboplatin, Vincristine (Feb 13, 2025)
- Carfilzomib (2023)
- Cetuximab (2023)
- CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) (2022)
- Cisplatin (Jan 13, 2025)
- Cisplatin, 5-Fluorouracil (Jan 13, 2025)
- Cisplatin, Cyclophosphamide, Etoposide, Methotrexate, Vincristine (2021)
- Cisplatin, Doxorubicin, Methotrexate (2021)
- Cisplatin, Etoposide (Jan 13, 2025)
- Cisplatin, Etoposide, Cyclophosphamide, Vincristine (Apr 4, 2025)
- Cisplatin, Gemcitabine (2022)
- Cisplatin, Vinorelbine (Jan 16, 2025)
- Cladribine (2023)
- Clofarabine (2023)
- Cyclophosphamide (2024)
- Cyclophosphamide, Carboplatin, Etoposide (Jan 1, 2025)
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Pegaspargase or Calaspargase, Thioguanine, Vincristine (2024)
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Pegaspargase or Calaspargase, Thioguanine, Vincristine, Nelarabine (2024)
- Cyclophosphamide, Cytarabine IV or SQ, Mercaptopurine (MP), Vincristine, and Pegaspargase or Calaspargase (2024)
- Cyclophosphamide, Cytarabine IV or SQ; Mercaptopurine (MP), Vincristine, and Pegaspargase or Calaspargase, Nelarabine (2024)
- Cyclophosphamide, Docetaxel (2022)
- Cyclophosphamide, Doxorubicin, Paclitaxel (Jan 25, 2025)
- Cyclophosphamide, Doxorubicin, Vincristine (2022)
- Cyclophosphamide, Topotecan (2024)
- Cyclophosphamide, Vinorelbine (Jan 29, 2025)
- Cytarabine (2022)
- Cytarabine (IT Ara-C) (2022)
D
- Dacarbazine (2022)
- Dactinomycin (2022)
- Dactinomycin, Doxorubicin, Vincristine (2022)
- Dactinomycin, Vincristine (2022)
- Daunorubicin (2022)
- Daunorubicin, Cytarabine Liposome (CPX-351) (2023)
- Daunorubicin, Pegaspargase or Calaspargase, Dexamethasone, Vincristine (2024)
- Daunorubicin, Pegaspargase or Calaspargase, Prednisone, Vincristine (2024)
- Dexamethasone (2022)
- Dexrazoxane (2024)
- Docetaxel (2024)
- Docetaxel, Irinotecan (2022)
- Docetaxel, Prednisone (2022)
- Doxorubicin (2024)
- Doxorubicin, Ifosfamide (2022)
E
- Epirubicin (2024)
- EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) (2022)
- Erlotinib (2022)
- Erlotinib, Gemcitabine (2022)
- Etoposide (2024)
- Etoposide, Ifosfamide (Feb 3, 2025)
- Everolimus (2024)
- Exemestane (2023)
F
- Filgrastim (2023)
- Fludarabine (2022)
- Fludarabine, Cytarabine (2022)
- Flutamide (2023)
- FOLFIRI (Leucovorin, 5-Fluorouracil, Irinotecan) (Jan 13, 2025)
- FOLFIRINOX (Leucovorin, 5-Fluorouracil, Irinotecan, Oxaliplatin) (Feb 7, 2025)
- FOLFOX (Leucovorin, 5-Fluorouracil, Oxaliplatin) (Feb 7, 2025)
- Fulvestrant (2023)
G
- Gemcitabine (2023)
- Gemcitabine, Paclitaxel Protein-Bound Particles (2023)
- Gemtuzumab Ozogamicin (2024)
- Goserelin (2023)
H
- Hydroxyurea (2023)
I
- Ibritumomab (2023)
- Idarubicin (2023)
- Ifosfamide (Jan 2, 2025)
- Imatinib (2024)
- Irinotecan (2024)
- Irinotecan, Temozolomide (2024)
- Isotretinoin (2023)
L
- Letrozole (2023)
- Leuprolide (2022)
- Liposomal doxorubicin (2022)
M
- Melphalan (Apr 4, 2025)
- Mercaptopurine (2023)
- Mercaptopurine PO, Methotrexate PO, Dexamethasone, Vincristine (2023)
- Mercaptopurine PO, Methotrexate PO, Dexamethasone, Vincristine, Nelarabine (2023)
- Mercaptopurine PO, Methotrexate PO, Prednisone, Vincristine (2022)
- Mesna (2022)
- Methotrexate (ITMTX) (2022)
- Methotrexate (not ITMTX) (2024)
- Methotrexate, Vinblastine, Doxorubicin, Cisplatin (2021)
- Methylprednisolone (2023)
- Mitotane (2023)
N
- Nelarabine (2023)
- Nilotinib (2024)
- Nilutamide (2023)
O
- Octreotide (2023)
- Oxaliplatin (2024)
P
- Paclitaxel (2024)
- Paclitaxel protein-bound particles (same as Nab-paclitaxel) (2023)
- Panitumumab (2024)
- Pegaspargase or Calaspargase (2024)
- Pegaspargase or Calaspargase, Vincristine (2024)
- Pegaspargase or Calaspargase, Vincristine, Methotrexate IV (2024)
- Pegfilgrastim (2023)
- Pemetrexed (2024)
- Pentostatin (2024)
- Ponatinib (2024)
- Prednisone (2022)
- Procarbazine (2022)
R
- Rituximab (2023)
S
T
- Tamoxifen (2023)
- Temozolomide (2023)
- Thioguanine (2022)
- Thiotepa (2023)
- Topotecan (2024)
- Trastuzumab (2024)
- Triple Intrathecals (Methotrexate, Cytarabine, Hydrocortisone) (2020)
- Triptorelin (2023)
V
- VAC (Vincristine, Dactinomycin, Cyclophosphamide) (2022)
- Vandetanib (2024)
- Velcade, Revlimid, Dexamethasone (2022)
- Vinblastine (2024)
- Vincristine (2024)
- Vincristine, cyclophosphamide (2024)
- Vincristine, Irinotecan (2022)
- Vincristine, Pegaspargase or Calaspargase, Prednisone (2024)
- Vinorelbine (2024)